注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
PTC Therapeutics Inc是一家科学驱动的全球生物制药公司。该公司致力于可为罕见疾病患者带来益处的临床差异药物的发现、开发和商业化。该公司拥有一个投资组合管道,其中包括商业产品以及处于不同开发阶段(包括临床、临床前以及研究和发现阶段)的候选产品,专注于针对罕见疾病和肿瘤等多种治疗领域的新疗法的开发。该公司有两种产品:Translarna(ataluren)和Emflaza(deflazacort),用于治疗杜兴型肌营养不良症(DMD)。该公司拥有一系列针对中枢神经系统(CNS)的罕见单基因疾病的基因治疗产品候选产品,其中包括用于治疗芳香L-氨基酸脱羧酶(AADC)的PTC-AADC和用于苯丙酮尿症(PKU)疾病的PTC923。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Michael Schmertzler | 69 | 2001 | Independent Chairman of the Board |
Alethia Rene Young | 43 | 2022 | Independent Director |
Mary L. Smith | 60 | 2021 | Independent Director |
Matthew B. Klein | 51 | 2020 | CEO & Director |
Stuart W. Peltz | 63 | 1998 | Co-Founder, Senior Consultant & Member of Scientific Advisory Board |
Allan Steven Jacobson | 77 | 1998 | Co-Founder, Chairman of Scientific Advisory Board & Independent Director |
William F. Bell | 67 | 2023 | Independent Director |
Stephanie Smith Okey | 63 | 2018 | Independent Director |
Joseph D. Puglisi | - | 2003 | Member of Scientific Advisory Board |
David P. Southwell | 63 | 2005 | Independent Director |
Jerome Bernard Zeldis | 74 | 2012 | Independent Director |
Marvin Wickens | - | - | Member of Scientific Advisory Board |
Robert J. Schneider | - | - | Member of Scientific Advisory Board |
Eric N. Jacobsen | 64 | - | Member of the Scientific Advisory Board |
Glenn Daniel Steele | 79 | 2015 | Independent Director |
Emma Reeve | 63 | 2018 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核